One Health Biosensing

Over $5B in exits from team creating Razorfish, One Drop, Big Foot, Welldoc, we're re-defining CGM

Last Funded May 2025

$201,466

raised from 143 investors

Highlights

1
A multi-modal AI-enabled health sensing platform designed to revolutionize the $10bn CGM market
2
A low-cost, painless, needle-free solution for >1Bn people with diabetes, pre-diabetes and obesity
3
Proprietary silicon micro-needle array technology, 10 years in R&D, protected by >50 issued patents
4
Demonstrated performance in >1,500 hrs of onbody clinical data with an estimated MARD of <10

Featured Investors

Invested $5,000
Syndicate Lead

Craig is the CEO of New York Cruise Lines, a marine-based sightseeing, entertainment and transportation business based in NYC.


“The market for CGM is expected to be explosive and expand rapidly as people start to monitor their blood glucose to manage diabetes, weight, and health. The AI-enabled, ultra-low cost, pain free, flexible One Health CGM is exactly what the market and payers want to keep people healthy. Today the 2 existing CGM players (Abbott and Dexcom) have products engineered for intensive insulin users and are high cost to payers. With One Health, people with Type 2 diabetes not on insulin, people on GLP-...”

[object Object] profile photo
[object Object] profile photo
[object Object] profile photo
[object Object] profile photo

Other investors include

 & 138 more


Our Team

Founder and CEO
A proven track record of successful entrepreneurship and disruptive innovation and over a decade of experience in digital design and the diabetes industry
Proven track record developing and launching diabetes devices
Proven expertise in data science, machine learning, and AI

One Health: Make sense of your health











When One Health is manufactured, we predict it will be the lowest cost CGM on the market

Future projections are not guaranteed.










Future projections are not guaranteed

Future projections are not guaranteed






Overview